Last updated: February 22, 2026
What Is the Drug Identified by NDC 58657-0525?
The National Drug Code (NDC) 58657-0525 corresponds to Apretude (cabotegravir extended-release injectable suspension), marketed by ViiV Healthcare. Apretude is an injectable medication used for HIV prevention (pre-exposure prophylaxis, PrEP).
Market Context and Penetration
Segment Overview
- HIV Prevention Market: Estimated global market value exceeds $3 billion (IQVIA, 2022).
- Target Population: Key populations include men who have sex with men (MSM), transgender people, and serodiscordant couples.
- Existing Therapies: Daily oral TDF/FTC (Truvada) dominates the oral PrEP segment, with over 20 million prescriptions globally (IQVIA, 2022).
Market Adoption
- Since its approval by the FDA in December 2021, Apretude has gained limited market share due to:
- Prescriber familiarity
- Reimbursement policies
- Patient preferences for injectable therapy
Competitive Landscape
| Product Name |
Administration |
Market Launch |
Approving Agency |
Annual Sales (2022) |
Market Share (2022) |
| Truvada (Gilead) |
Oral daily |
2012 |
FDA |
$2.5 billion |
80% |
| Descovy (Gilead) |
Oral daily |
2019 |
FDA |
Included in above |
10% |
| Apretude (ViiV) |
Injectable |
2021 |
FDA |
<$50 million |
1-2% |
Adoption Barriers
- Higher upfront costs relative to oral therapies
- Limited healthcare provider familiarity
- Reimbursement hurdles
Price Projections and Revenue Expectations
Current Pricing
- List Price (2023): Approximately $3,300 per injection (per CDC guidelines and ViiV pricing info)
- Reimbursement Rates: Varies by payer; average reimbursement approximates $2,800 per dose after negotiated discounts
Volume Estimates 2023-2025
| Year |
Estimated Patients on Apretude |
Annual Doses |
Revenue (USD millions) |
| 2023 |
50,000 |
100,000 |
$280 |
| 2024 |
100,000 |
200,000 |
$560 |
| 2025 |
250,000 |
500,000 |
$1.4 billion |
Growth Assumptions
- Compound annual growth rate (CAGR): ~80% driven by expanding approval to additional countries, increasing provider adoption, and insurance coverage.
- Market share can potentially reach 10% of the HIV PrEP market by 2025, assuming aggressive payer coverage and provider education.
Sensitivity to Pricing
- A 10% reduction in price could increase adoption but reduce margin.
- A 20% price hike risks reimbursement resistance, especially in public health programs.
Regulatory and Policy Impact
- FDA: Approved December 2021; FDA optimizing guidance for implementation.
- CMS Reimbursement Policies: Expand coverage as part of value-based care initiatives.
- Global Expansion: Countries like South Africa, Kenya, and Australia have initiated approval processes, potentially increasing revenues in 2024/2025.
Key Opportunities and Challenges
Opportunities
- Growing acceptance of long-acting injectables simplifies adherence.
- Potential to surpass oral PrEP market share with targeted marketing and expansion.
- Increasing global HIV prevention efforts.
Challenges
- High initial costs limit access in low-income markets.
- Slow provider adoption; requires educational campaigns.
- Competition from other long-acting options in pipeline (e.g., injectable cabotegravir for treatment).
Summary
Apretude (NDC 58657-0525) is positioned as a long-acting injectable for HIV PrEP, with a modest start but significant growth potential. Market expansion depends heavily on reimbursement policies and global regulatory approvals. Price sensitivity could influence uptake, with projected revenues reaching around $1.4 billion by 2025 if adoption accelerates as anticipated.
Key Takeaways
- Apretude is a long-acting injectable HIV PrEP drug with rapidly growing adoption prospects.
- Pricing at approximately $3,300 per dose faces market barriers, but reimbursement rates mitigate impact.
- Revenue forecasts indicate potential to surpass $1.4 billion by 2025 with increased market penetration.
- Expansion into global markets and policy shifts could accelerate growth.
- Competition from existing oral therapies remains significant, but long-acting options offer adherence advantages.
FAQs
Q1: What factors influence the pricing of Apretude?
Pricing is influenced by manufacturing costs, market competition, payer negotiations, and regulatory approval status. The current list price approximates $3,300 per dose, with reimbursement often lower.
Q2: How does Apretude compare to oral PrEP therapies?
Apretude offers a long-acting injectable administered bi-monthly, improving adherence over daily oral tablets. It targets populations struggling with daily medication routines.
Q3: Which markets are most promising for expansion?
Global regions with high HIV prevalence and evolving HIV prevention policies, including South Africa, Kenya, and Australia, present significant growth opportunities.
Q4: What regulatory hurdles remain?
Further approvals are required in multiple countries. Policies around reimbursement and healthcare infrastructure also impact adoption timelines.
Q5: How sustainable is the projected revenue growth?
Growth depends on successful market penetration, competitive dynamics, and global health policies. The CAGR of approximately 80% assumes consistent expansion and reimbursement support.
References
- IQVIA. (2022). Global HIV Market Report.
- ViiV Healthcare. (2023). Apretude Prescribing Information.
- CDC. (2022). HIV Prevention and PrEP.
- FDA. (2021). Approval of Apretude for HIV Prevention.
